In This Section

Peter N. Walsh, MD, PhD

Professor Emeritus, Medicine
Professor, Sol Sherry Thrombosis Research Center
Professor, Fels Institute for Cancer Research and Molecular Biology
Professor, Biochemistry

Peter Walsh
Contact Information

Contact Information

Phone

215-707-4375

Email

pnw@temple.edu
About Me

Research Interests

Molecular and Cellular Interactions of Blood Coagulation Factor XI.

NIH-funded research focuses on the characterization, intermolecular interactions and structure-function relationships of coagulation proteins, including Factor XI.

Molecular Interactions of Factor XI.

Recent observations resulting in the recognition of the essential role of FXI in hemostasis concern the relationship of its domain structure to its biological function, the molecular genetics of FXI, its molecular and cellular interactions, the elucidation of newly discovered pathways for activation of FXI, and the expression and regulation of its enzymatic activity. The long-term goals of this project are to elucidate the molecular mechanisms involved in the interaction of FXI with protein and cell surface ligands involved in its activation and in the expression and regulation of FXIa enzymatic activity.

Exosite Function in the Catalytic Domain of Coagulation Factor XIa.

The long-term goals of this project are to elucidate the molecular mechanisms involved in the interaction of FXIa with its substrate, its cellular (platelet) receptor(s) and its regulators, including the platelet-secreted Kunitz inhibitor, protease nexin-2 and to define the structural biology mediating the exposure of exosites within the catalytic domain that result from the conversion of the zymogen to the protease.

Antithrombotic Effects of FXIa Inhibition by the KPI Domain of PN2.

The goals of this project are to determine the mechanism by which the kunitz protease inhibitor (KPI) domain of protease nexin-2 (PN2) prevents thrombosis and stroke in mice; to study mutant forms of KPI with increased antifibrinolytic and decreased anticoagulant activity; and to develop antithrombotic gene therapy using KPI. The ultimate goal of the proposed work is to develop a new class of anticoagulants to provide safe and effective treatment and prophylaxis of diseases characterized by excessive blood clotting.

Education, Training & Credentials

Educational Background

  • Research Fellow, Blood Coagulation (NIH Special Postdoctoral Research Fellowship), Oxford Haemophilia Centre, Churchill Hospital, England, 1969-1972
     
  • D.Phil., Bio-Med. Sciences, University of Oxford, Oxford, England, 1972
     
  • Medical Liaison Officer, Urokinase Pulmonary Embolism Trial, National Institutes of Health, Bethesda, MD, 1966-1969
     
  • Chief Resident, Medicine, Barnes Hospital, St. Louis, MO, 1965-1966
     
  • Senior Resident, Medicine, Palo Alto-Stanford Hospital, Palo Alto, CA, 1964-1965
     
  • Medicine Fellow, Hematology, Washington University School of Medicine, St. Louis, MO, 1963-1964
     
  • Assistant Resident, 1962-1963, Medicine Intern, 1961-1962, Barnes Hospital, St. Louis, MO
     
  • MD, Medicine, Washington University School of Medicine, St. Louis, MO, 1957-1961
     
  • AB, Pre-Medicine, Amherst College, Amherst, MA, 1953-1957
Publications

PubMed Publications

View PubMed Publications